Sector News

Takeda, GSK veteran takes the helm at Sangamo

June 1, 2016
Life sciences

Big Pharma veteran Dr. Alexander (Sandy) Macrae has taken on the role of president and CEO of Californian biotech Sangamo Biosciences after the retirement of its former head Edward O. Lanphier, who will become the company’s chairman.

The company said that Lanphier has retired from his position as the company’s president and CEO effective today, and will become its new non-executive chair later this month. Its new leader Dr. Macrae, 53, comes with a long service history in the Big Pharma arena, previously being the global medical officer of Takeda from 2012 to March 2016. Dr. Macrae also held various positions at GlaxoSmithKline since 2004. He was educated in the U.K.

The company focuses on gene editing technology, with trials ongoing in HIV/AIDS and hemophilia A and B, and currently has a market cap of around $500 million.

In a SEC filing announcing the change, the company disclosed that Dr. Macrae will receive a base salary of $600,000 per year, while also being able to gain an annual cash bonus should the company hit its targets.

And that’s not all–Dr. Macrae will also be given $200,000 as a “sign-on bonus”–although that will need to be returned should he leave “without good reason” within the next year. He can also purchase up to 700,000 shares of common stock of the company.

The biotech has had mixed fortunes in recent months after Shire ended its 3-year gene editing pact, with each company hanging on to the programs best aligned to its goals.

The pair joined up in 2012 when Shire paid $13 million up front and promised undisclosed millions more to work with Sangamo on so-called ZFP therapeutics, lab-crafted proteins designed to interrupt DNA sequences and correct genetic defects.

But in fall of last year the two split up, with Shire handing back the rights to early-stage, ZFP-powered treatments for hemophilia A and B but keeping some Sangamo-discovered leads in Huntington’s disease and another undisclosed target.

The company’s $320 million deal with Biogen focused on hemoglobinopathies–such as sickle cell disease and beta-thalassemia–is however still on.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.